Innovative Pharma
The large originator companies that invest heavily in R&D and drive global therapeutic innovation
Insight across discovery, development, and deal-making
Pharmaceutical companies are managing rapid scientific progress alongside significant commercial and regulatory pressures. Oncology, immunology and rare diseases continue to attract investment, yet rising R&D costs, patent expiries, complex pricing environments and competition from biotech mean that success depends on more than strong science. Companies must balance innovation with portfolio discipline and capital efficiency.
We support pharma leaders in navigating these dynamics with clear, evidence-based advice. Our work includes in-licensing, out-licensing and M&A, where we assess opportunities against competitor pipelines, benchmark valuations, and design transaction structures that share risk while maximising long-term value.
Our innovative pharma leads
Our teams combine scientific knowledge with commercial and transaction experience. We analyse therapeutic pathways, regulatory trends, pricing and market access benchmarks, and potential partner capabilities to give a clear view of both risks and upside. This ensures decision-making reflects on-the-ground realities, not just headline forecasts.
Beyond transactions, we help management teams strengthen commercial excellence through go-to-market strategy, pricing, target operating models, digital and data use, and post-acquisition integration. This holistic approach supports innovative pharma companies in capturing the full value of their pipelines while building resilience for the future.
News & Insights
